Merz Therapeutics

CompanyGermany

Merz Therapeutics develops 2 assets, the furthest approved (levodopa in Parkinson). Mostly small molecule acting on GRIN2B, GRIN1 and GRIN2A; based in Germany.

2
Assets
Furthest: Approved; 3
Trials: 0
Signals

Pipeline

levodopa
Inhaled dopamine precursor converting to dopamine in the brain to treat OFF episodes
Approved, Small molecule, Parkinson, Parkinson's disease
memantine
Uncompetitive NMDA receptor antagonist protecting against glutamate excitotoxicity
Approved, Small molecule, GRIN2B, GRIN1, Alzheimer's disease, dementia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms5
Trials5
Similar companies6

Updated 9 Oct 2026 · 46 sources